Ekf Diagnostics Share Discussion Threads

[rivaldo] 11/1/2021 07:33

News from Verici this morning for the record:



"Additional patent licence with Mount Sinai

Worldwide exclusive licence to liquid biopsy IP for predicting risk of fibrosis and chronic damage rejection

Strengthens patent portfolio covering the entire kidney transplant diagnostic pathway

etc"

[the shuffle man] 09/1/2021 18:58

I have the Trellus shares showing on my share centre account in the correct ratio

[pldazzle] 09/1/2021 18:19

I have emailed the company as follows:

Dear Sirs

I hold x,xxx Ordinary shares in EKF Diagnostics PLC.

I have received a letter from yourselves - signed in facsimile by Salim Hamir, Company Secretary - stating that I now hold x,xxx "Dividend Trellus Shares". This is the same number as my holding of EKF shares. I am aware that at least one other shareholder has received a similar letter.

Contrariwise, EKF's successive RNS announcements have stated that the dividend in specie was to be in the ratio 1 Trellus : 16.25 EKF. By my reckoning, accordingly, I should now be the holder of yyy Trellus shares rather than x,xxx.

Can you please confirm (a) that the letter I received is authentic and genuine, and (b) that it is incorrect and that a replacement letter will be sent out.

On a separate matter, can you please let me know when and in what form the value of the dividend in specie will be announced. This is for the purposes of my 2020/21 tax return, which I wish to submit promptly this year.

Yours faithfully

[james188] 09/1/2021 16:27

I have also received a letter from EKF (or at least on their letter head) which shows the number of Trellus shares allocated as equal to my EKF holding. However, my CS Direct account correctly shows an allocation of 1:16.25.

The shares are locked in and not tradeable, so I am inclined to think that this is an error rather than a scam. I expect that the company will clarify on Monday. If not, I will contact them.

[pldazzle] 09/1/2021 16:10

wan ... many thanks, but this letter is on official EKF letterhead and is signed by Salim Hamir, company secretary. I am confident that it's authentic: the language is formal, and in all other respects, the letter reiterates the terms of the 14 December RNS, including e.g. details of the Lock-up Period.

I am well aware of boiler room scams (my nephew is a QC who prosecutes them!) and do not take cold phone calls. Nor would I be interested in selling my EKF or Trellus shares anyway.

The letter ends: If you have any questions, please contact us through our investor relations: Tel. [phone]. Email: [e-mail]. The phone number I don't recognise, but the email address is as per EKF's website I will email them to find out what's going on.

[wan] 09/1/2021 16:03

Following on from highlighting the recent PerkinElmer acquisition, the following article also covers the acquisition rationale and the TB opportunity -

PerkinElmer inks $591M Oxford Immunotec buy to challenge Qiagen in TB market

PUBLISHED
Jan. 8, 2021

Dive Brief:
PerkinElmer has struck a deal to buy tuberculosis test provider Oxford Immunotec for $591 million, positioning it to compete with Qiagen for the infectious disease market.

The deal will give PerkinElmer control of the T-SPOT.TB test, a diagnostic that measures T cells against Mycobacterium tuberculosis antigens to detect active and latent TB infection. Oxford Immunotec product sales hit $69.8 million in 2019, up 28% over the prior year, but were negatively impacted by COVID-19 in 2020.

The test will slot into a portfolio of other immunodiagnostics at PerkinElmer, many of which it acquired in back-to-back takeovers of Euroimmun and Tulip in 2017.

Dive Insight:
The deal marks the fourth for medtech this week, following Hologic's two acquisitions in the women's health space and Stryker's acquisition of the orthopaedic technology company OrthoSensor.

Some analysts expect a wave of dealmaking this year amid a combo of ready capital and distressed assets.

Oxford Immunotec competes for the TB blood test market with Qiagen’s QuantiFERON-TB Gold in-Tube test. Some studies have found T-SPOT.TB to be more sensitive and cheaper than its rival. Oxford Immunotec values the quantified TB testing market at $1 billion, suggesting it is currently only scratching the surface of the opportunity.

PerkinElmer is now set to be the company that tries to realize that opportunity and expects the acquired assets to grow faster than its broader diagnostics franchise for the foreseeable future. The existing diagnostics franchise grew 93% in the third quarter, driven by sales related to COVID-19. Other parts of PerkinElmer’s business were negatively affected by the crisis, with non-COVID-19 immunodiagnostic sales only 80% to 90% normalized by the third quarter.

Speaking to investors on a third quarter results conference call, PerkinElmer CEO Prahlad Singh said “there are several other new immunodiagnostic assays that we are either working on in-house or also looking at inorganic opportunities."

Full story -

[wan] 09/1/2021 15:52

pldazzle...That really doesn't sound right and the ratio is indeed incorrect, so it's possibly the initial stage of a scam attempt! Thus, you may get a phone call next -

How share and bond scams work
Share and bond fraud usually comes out of the blue, with scammers cold-calling investors after taking their phone number from publicly available shareholder lists.

The high-pressure sales tactics can also come by email, post, word of mouth or at a seminar.

These scams are sometimes advertised in newspapers, magazines or online as genuine investment opportunities. They may even offer a free research report into a company, or a free gift or discount on their dealing charges.

You will often be told that you need to make a quick decision or miss out on the deal.

The scammers might also try to sell you shares or bonds in a company that doesn’t exist.

If you already own shares in a company, you may receive a call from someone offering to buy them at a higher price than their market value.

The scam will request the money upfront as a bond or other form of security, which they say they’ll pay back if the sale doesn’t go ahead – but you’ll never hear from them again.

[pldazzle] 09/1/2021 15:32

I have received a letter from EKF dated 8 January - have others received one too? - purporting to confirm that I am the holder of [x] number of "A ordinary shares of nominal value £0.0001 each in Trellus Health Limited (the 'Dividend Trellus shares'". [x] is the identical number of shares as my holding in EKF, i.e. according to this letter I now hold 1 Trellus share for each 1 EKF share.

EKF's RNS of 14 December stated:

"The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share [sic] held in the Company."

Which is it then: 1 for 1, or 1 for 16.25? Has the company or its registrar slipped up?

[wan] 08/1/2021 07:49

Longhorn TB screening test -

THE PROBLEM

The global effect of latent tuberculosis (TB).
With a large amount of the world’s population being affected with latent TB, testing has become essential. Latent TB tests determine if the individual has been exposed to TB and the individual's immune system generated a response. However, these tests cannot distinguish between drug sensitive and Multi-Drug Resistant TB (MTB), which is increasingly common in many countries. In some countries, latent TB is treated with a 6-9-month course of antibiotics.

PrimeScreen™ MTB provides a new way to screen patients with latent TB, individuals that have been actively exposed to MTB-infected individuals, and symptomatic patients that cannot produce sputum or adequate sputum for standard testing. Individuals that have TB in their oral cavity are likely to be spreaders and should undergo further evaluation to prevent transmission.

~1/4 of the world's population has latent tuberculosis.

[wan] 08/1/2021 07:42

As previously mentioned, although Covid-19 testing is in ever greater demand, as EKF investors, we do also need to cast our eye beyond Covid-19 testing, especially now that Longhorn, and indeed EKF, has been put firmly on the testing/surveillance map.

In this regard Longhorn Vaccines already have a screening test for TB.

So, to highlight the importance (and size) of the TB market, I was interested to note that yesterday (US time) PerkinElmer announced it is to acquire Oxford Immunotec Global PLC -

Through this Acquisition, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world.

[wan] 08/1/2021 07:19

Source Bio now offer Government approved 'Test to Release' Covid-19 Antigen RT-PCR tests.

You can reduce your self isolation time when arriving back from your holiday or business trip. Order online:

[wan] 08/1/2021 07:12

7th January 2021

EKF fly the extra mile over Christmas

EKF fly the extra mile over Christmas
PrimeStore - EKF fly the extra mile over Christmas 3

Like Santa, the EKF Diagnostics logistics team took to the skies over the Christmas holidays. Faced with the problem of sending 160,000 tubes of PrimeStore MTM to a customer in Ireland with a tight deadline and the uncertainty around border control due to the Brexit negotiations, the team at EKF’s Barleben facility charted an aircraft and flew 18 pallets directly to Dublin Airport.

Thanks to the efficiency of our team and their colleagues at DB Schenker the consignment reached Dublin within three hours, ready to be collected by our distributor, Syntec.

[firtashia] 06/1/2021 19:25

Petewy- Dont know about you but what I really enjoy about investing in small caps such as EKF & those others you listed is that by carrying out fundamental research you can take up a position in the stock well before “Mr Market” - in this case Liontrust- belatedly cottons on/is able to take up a significant position. As Peter Lynch said, “when a company I talk to tells me the last analyst showed up 3 years ago, I can hardly contain my enthusiasm”.

[chris16041] 06/1/2021 18:06

Because you're a fathead old chap

Toodle pip

[chris16041] 06/1/2021 18:06

Because you're a fathead old chap

Toodle pip

[tongosti] 06/1/2021 16:32

Funny following I have - I wonder why.

[petewy] 06/1/2021 16:09

Agreed Riv I made money with Techinvest, very thorough.
Filter Tong MG he's a nuisance on SDI MWE and JET2

[tongosti] 06/1/2021 15:53

Haha - my fav village in chief!

[mg1982] 06/1/2021 15:50

If anyone wants to check the credibility of this Tong poster please see the SDI BB and my recent exchange exposing his lies there

[tongosti] 06/1/2021 15:37

My 920 post on this board posted precisely 56 days ago chaps: 09:06 Odds for a meaningful (at least) major consolidation (or worse!) around existing levels have risen to 93% including last Friday's data.Fair to say that two months down the line this has come to pass ain't it. Now the question is - what is the next path of least resistance? I am flat but willing to go back long IF Mr Market gives me a hint. Until he does so - relaxing and biding my time.

[rivaldo] 06/1/2021 15:18

Indeed. I posted it there since it was relevant to ORPH (and CNIC too) as well as EKF.

Techinvest is imo an excellent tip sheet, one of if not THE best around along with SCSW. Their portfolios over many years have performed outstandingly well overall.

If they were to buy EKF for their portfolio it would likely result in additional interest here. Which is never a bad thing.

Apologies to others here for having to post this!

[faz] 06/1/2021 13:57

You also posted this on the Orph site Rivaldo. It's just a perennial tip sheet as old as me.

[wan] 06/1/2021 09:00

So no doubt readers will no get my drift with regards to the recent investment fund purchases in EKF!